Friday, 24 Jan 2020

You are here

Reports Call for More Gout Education

Two recent surveys show that gout patients are often uninformed, undertreated, improperly monitored and frequently stigmatized by their gout.

The Gout & Uric Acid Education Society (GUAES) has done an online survey of 1000 Americans and 103 gout patients and shown that nearly 90% of patients view gout as a "major inconvenience" and worrisome.

Although 90% view gout as a serious health issue, they found far fewer taking steps to prioritize their treatment. More than half of gout patients admitted that treating their gout is not a priority, only half visit their physician regularly, and just one in three maintains a healthy fitness level.  

Equally concerning is that only 27% had their uric acid levels tested within the past six months. Only 40% were receiving uric acid-lowering medications, and an equal amount incorrectly believe that they only need to take medications when they are having a flare. 

Despite the prevalence of gout (8.3 million Americans), the survey found that 71% of Americans and 55% of gout patients don't even think of gout as being a type of arthritis.

In addition to a general lack of understanding of what gout is and can do to the body, the survey confirmed that a stigma exists when it comes to addressing gout. More than half of gout sufferers surveyed (52 percent) say they are embarrassed to have it, and nearly half (46 percent) believe it's their fault that they have it.

Another recent report in Arthritis Care and Research reviewed depictions of gout in the 21 highest circulation newspapers in the United Kingdom and United States between 2010 and 2015.  (Citation source 

Social embarrassment due to gout was reported in 27 of 114 (23.7%). Jokes or humorous references to gout were reported in 30 of the 114 articles (26.3%). In addition, dietary solutions were over-emphasized compared with effective medication.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

Predicting Inpatient Gout Flares

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare:

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.